Danaher Corporation $DHR Shares Sold by Lansforsakringar Fondforvaltning AB publ

Key Points

• Lansforsakringar Fondforvaltning AB sold 7,503 shares of Danaher Corporation, reducing its holdings by 3.4% to 210,803 shares, which were valued at approximately $43.2 million.
• DHR's latest quarterly earnings of $1.80 per share exceeded analysts' expectations of $1.64, with revenues of $5.94 billion for the quarter, marking a 3.4% increase from the previous year.
• The stock has received a mix of analyst ratings, with an average rating of "Moderate Buy" and a target price of $247.61, while institutional investors currently hold 79.05% of the company's stock.

Lansforsakringar Fondforvaltning AB publ reduced its position in Danaher Corporation (NYSE:DHR - Free Report) by 3.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,803 shares of the conglomerate's stock after selling 7,503 shares during the quarter. Lansforsakringar Fondforvaltning AB publ's holdings in Danaher were worth $43,215,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. FAS Wealth Partners Inc. boosted its holdings in Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after acquiring an additional 1,639 shares during the period. MGO One Seven LLC lifted its position in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after purchasing an additional 20,813 shares during the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in shares of Danaher during the first quarter valued at $539,000. Horizon Financial Services LLC grew its holdings in shares of Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc increased its stake in Danaher by 6.1% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock worth $7,126,000 after buying an additional 2,009 shares during the period. Institutional investors own 79.05% of the company's stock.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 0.4%

NYSE DHR traded up $0.80 during midday trading on Friday, hitting $206.09. 1,979,809 shares of the company traded hands, compared to its average volume of 3,319,294. The company has a market cap of $147.57 billion, a PE ratio of 43.85, a price-to-earnings-growth ratio of 2.87 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company's 50-day simple moving average is $201.65 and its 200-day simple moving average is $199.49.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the company posted $1.72 EPS. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DHR. Wells Fargo & Company decreased their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Barclays reiterated an "overweight" rating and set a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Evercore ISI lowered their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, Guggenheim restated a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.